Fractional CO2 Laser Therapy for Survivors of Gynecologic Malignancies
This randomized pilot trial studies how well fractional carbon dioxide (CO2) laser therapy works in minimizing genitourinary syndrome of menopause (GSM) in gynecological cancer survivors. Fractional CO2 laser therapy may reduce symptoms of GSM in survivors of gynecologic cancers.
• Women with cervical, endometrial, vaginal, vulvar or ovarian cancer who have completed all cancer related treatment \>= 6 months prior to enrollment
‣ Any form of hysterectomy, including radical hysterectomy permitted
⁃ Must have no evidence of recurrent disease on pelvic exam within past 3 months
⁃ Radiation therapy is permitted but not required
• Patient reported dyspareunia and/or vaginal dryness with severity of \>= 4 on a scale from 0 (none) to 10 (most severe) that has been persistent over \>= 4 weeks and/or the inability to be sexually active due to pain